UK Public Sector Contracts & Tenders

The UK Health Security Agency (UKHSA) intends to establish a Framework Agreement for the provision of Countermeasures and Preparedness products (the “Framework Agreement”). The Framework Agreement will be available for use by UKHSA and potentially other eligible public sector organisations such as the Ministry of Defence (MOD). The Framework Agreement will provide access to a range of pre-approved suppliers and their products. At this stage, it is intended that the Framework Agreement will comprise multiple lots including, but not limited to: - Antivirals - Antibiotics - Antitoxins - Antivenoms - Antidotes - Vaccines - Immunoglobulins - Intravenous Fluids (IV's) - ICU Medicines - Radiation Treatments - Medical Consumables (used in administering the medicines)* - Combined Needles and Syringes* *For the purposes of preliminary market engagement, we have included all products in scope of our portfolio. To confirm, recently awarded contracts will continue for their term.  The proposed scope and lotting structure will be explored further during the preliminary market engagement, with the final lotting structure confirmed in the UK 4 Tender Notice for this procurement. Suppliers will be awarded places on the Framework Agreement based on their ability to meet quality standards and deliver value for money. UKHSA is committed to working with suppliers who support Sustainability and Social Value objectives, and these elements are expected to form part of the award criteria, details of which will be set out in the tender documentation.

The UK Health Security Agency (UKHSA) wishes to establish contracts for the provision of measles, mumps and rubella (MMR) vaccine

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Botulinum Antitoxin Heptavalent (HBAT) through this Request for Information (RFI), in accordance with the Procurement Act 2023. The purpose of this exercise is to gather information on available products, supplier capability, and market conditions to inform a potential future procurement.

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Prussian Blue through this Request for Information (RFI), in accordance with the Procurement Act 2023. The purpose of this exercise is to gather information on available products, supplier capability, and market conditions to inform a potential future procurement.

The purpose of this document is to enhance the Authority’s understanding of the marketplace and its options for sourcing for a potential future requirement. The issuance of this request for information (RFI) does not constitute a sourcing exercise nor will the Authority pay any costs incurred in the preparation of a response to this RFI. The UK Health Security Agency’s (UKHSA) key objectives for this RFI are: understand the ability of the marketplace to fulfil its requirements; refine the scope of the requirements to best align to the marketplace; and inform the Authority’s chosen route to market to best enable competition The key dates for this RFI are as follows: RFI Published: 30th June 2026 RFI Response: 14th July 2026 Should you have any questions or queries relating to this RFI, please use the Atamis portal’s messaging centre to direct your questions to us for a response. If a response is not received by the RFI response deadline this will have no impact on your ability to tender for the opportunity in the future. UKHSA will not enter into contracts on the basis of replies to this RFI.   Description of Scope of Requirements: The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure. Background: UKHSA is seeking to engage with the market to better understand supplier capability for the provision of lyophilisation (freeze-drying) services for X-ray irradiated pathogens to provide greater resilience and flexibility across use cases as part of UKHSA’s Pandemic Preparedness strategy. UKHSA requires support in developing optimal formulations and lyophilisation processes to ensure that irradiated, inactivated pathogens can be safely stored, handled, and distributed for diagnostic use and pandemic preparedness. Lyophilisation is required to enhance the long-term stability and usability of these materials, supporting strategic resilience and response capabilities. Requirements: We need the supplier to have: • Ability to handle irradiated, inactive viral and bacterial material in liquid medium • Ability to develop and optimise lyophilisation protocols including assessment of different stabilisation matrices • Appropriate quality system in place (at least ISO 9001) to ensure consistency and traceability • Provide product quality control (QC) testing of final product, including thermal stability and absence of contaminants. • Overall aim is to lyophilise up to 20 pathogens over the next 4 years o Estimated vial volume for lyophilisation is 0.3mL – 2mL o Estimated batch size for lyophilisation is 6 – 100mL o Estimated number of batches per year is 5 Should you wish to respond to this Request for Information, please complete the response questionnaire which is found at the following link: https://atamis-1928--prospend.vf.force.com/apex/CS_ContractPage?filters=&page=1&Preview=Yes&searchStr=&SearchType=Projects&sortStr=Alphabetical&uid=a07Pz00001jEyqdIAC&sfdcIFrameOrigin=https%3A%2F%2Fatamis-1928.lightning.force.com

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Pralidoxime Chloride through this Request for Information (RFI), in accordance with the Procurement Act 2023. Suppliers wishing to be considered for inclusion in this procurement exercise must confirm their participation by the stated deadline. Suppliers who do not participate will not be included in the procurement process or considered for subsequent stages.

The key dates for this RFI are as follows: RFI Published: 28 August 2026 RFI Response: 11 September 2026 Should you have any questions or queries relating to this RFI, please use the Atamis portal’s messaging centre to direct your questions to us for a response. If a response is not received by the RFI response deadline this will have no impact on your ability to tender for the opportunity in the future. UKHSA will not enter into contracts on the basis of replies to this RFI.   Description of Scope of Requirements: The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure. Background: The UKHSA Sequencing Laboratories in Bristol, Colindale, Manchester, and Porton Down offer nucleic acid sequencing services to support a variety of public health and clinical functions. These services currently include ongoing pathogen surveillance programmes, clinical metagenomics sequencing, and outbreak detection. As part of the UKHSA Pathogen Genomics Strategy and Pandemic Preparedness Programme, we are looking to maintain and expand the capacity and efficiency of our Genomics services. We therefore wish to explore available liquid handling robotics to support sequencing laboratory processing. Should you wish to respond to this Request for Information or require more information, please follow the link below: https://atamis-1928--prospend.vf.force.com/apex/CS_ContractPage?filters=&page=1&Preview=Yes&searchStr=&SearchType=Projects&sortStr=Alphabetical&uid=a07Pz00001uBE2zIAG&sfdcIFrameOrigin=https%3A%2F%2Fatamis-1928.lightning.force.com

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Doxycycline 10 pack through this Request for Information (RFI), in accordance with the Procurement Act 2023.